Blockchain Registration Transaction Record

BetterLife Pharma's Non-Hallucinogenic LSD Derivative Targets Brain Disorders

BetterLife Pharma advances BETR-001, a non-hallucinogenic LSD derivative for TBI and migraines. Human trials planned for 2026, offering new hope for neurological disorders.

This development matters because it addresses critical limitations in current psychedelic-based therapies for mental health and neurological conditions. Traditional treatments often require controlled, clinical settings due to hallucinogenic effects, creating barriers to access, high costs, and logistical challenges for patients. BETR-001's non-hallucinogenic profile could revolutionize treatment by enabling at-home administration, expanding availability, and potentially reducing healthcare burdens. For millions suffering from treatment-resistant depression, TBI, migraines, and cluster headaches—conditions with significant unmet needs—this innovation offers hope for more effective, convenient, and scalable solutions. It also reflects a broader trend in biotech toward safer, patient-centric drug development, potentially accelerating acceptance and integration of novel compounds into mainstream medicine.